Paris And London

PARIS and LONDON, November 29, 2011 - Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE/LSE: AZN) announced today that the European Commission has granted marketing authorisation for KOMBOGLYZETM (saxagliptin and metformin HCl immediate-release fixed dose combination) that will cover the 27 Member States of the European Union.

PARIS and LONDON, November 16, 2011 - Three new phones with deep Facebook integration and dedicated 'F' key available in Africa and Europe from Q4 2011 - offering the widest portfolio of affordable phones with deep Facebook functionality launched by an operator to date Orange is bringing simple, affordable, social phones for under €100 to a broader range of customers in more than 15 countries* The new range includes the ALCATEL ONE TOUCH 908F Android smartphone, one of the most affordable Android smartphones available, exclusive to Orange Orange will exclusively launch three new affordable phones with deep Facebook integration across Africa and Europe from Q4 2011, creating a swift, simple, cost effective social experience for more of Orange's customers than ever before.

PARIS and LONDON, August 1, 2011 - - ToManageaSignificant PortionofIndirect SpendonBehalfof L'Oral,Making This the Largest Procurement ContractbySpendfor Xchanging.

PARIS and LONDON, March 4, 2011 - Bristol-Myers Squibb Company (www.bms.com)(NYSE: BMY) and AstraZeneca (www.astrazeneca.com) (NYSE: AZN)today announced that the European Commission has approved a label update for ONGLYZA(R) (saxagliptin) in the treatment of adults with type 2 diabetes who have moderate or severe renal impairment.

PARIS and LONDON, March 4, 2011 - In the news release, "ONGLYZA(R) Becomes the First DPP-4 Inhibitor Available for Use in Europe" issued on 4 Mar 2011 08:00 GMT, by Bristol-Myers Squibb and AstraZeneca NYSE:AZN over PR Newswire, we would like to advise that the headline was incorrectly transmitted by PR Newswire and should have read "ONGLYZA(R) Becomes the First DPP-4 Inhibitor Available for Use in Europe in Type 2 Diabetes Patients With Moderate or Severe Renal Impairment" rather than "ONGLYZA(R) Becomes the First DPP-4 Inhibitor Available for Use in Europe".